The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
Academic rigor, journalistic flair
Articles on Drug approval process
Displaying all articles
As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
The FDA receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Law, Wake Forest University
-
Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
-
Professor of Economics, University of Calgary
-
Associate professor, School of Public Health, University of Alberta
-
Professor of Health Economics, Queen's University Belfast
-
Professor, School of Population and Public Health, University of British Columbia
